Abstract
We aimed to investigate the prevalence of comorbidities in cervical cancer survivors compared with the general population and to identify risk factors and impact on their quality of life (QoL). 860 female cervical cancer survivors enrolled at six tertiary hospitals and 994 women from the general population were surveyed on current comorbidities and QoL (EORTC QLQ-C30 and QLQ-CX24). Compared with the general female population, the cervical cancer survivors reported higher prevalence of comorbidities (0.93 +/- 2.91 vs. 0.37 +/- 0.67, p < 0.01), significantly more heart disease (adjusted odds ratio (aOR), 2.64; 95% confidence interval (CI), 1.38-5.07), liver disease (aOR, 3.29; 95% CI, 1.54-7.02), hypertension (aOR, 1.72; 95% CI, 1.30-2.27), gastrointestinal disease (aOR, 1.79; 95% CI, 1.37-2.33) and musculoskeletal disease (aOR, 1.94; 95% CI, 1.45-2.59). Heart and renal disease significantly influenced QoL in many subscales. Patients with diabetes or cerebrovascular disease had an increased likelihood of sexual problems. The cervical cancer survivors had more comorbidities than the general population, and that in turn affected their QoL. Vigilant follow-up of comorbidities should be incorporated into in the care of cancer survivors.
Citations
Jan 16, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Dong Wook ShinJin Young Choi
Feb 20, 2010·Cancer Causes & Control : CCC·Dong Wook ShinYoung Ho Yun
Apr 27, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Dong Wook ShinJong-Hyock Park
Nov 6, 2013·Nature Reviews. Cardiology·Susanna Price, Elizabeth Haxby
Apr 4, 2012·Annals of Surgery·Young Ho YunJae Ill Zo
Feb 22, 2012·Chemotherapy·Derek WeyckerGary Lyman
Jul 1, 2008·Biomedical Imaging and Intervention Journal·D E HeronJ W Mucenski
May 1, 2011·Pain Management·N Lynn Henry
Aug 2, 2013·Future Oncology·Niki Karachaliou, Rafael Rosell
Apr 6, 2011·Future Oncology·Stephane Oudard
Mar 17, 2009·Future Oncology·Philip M ArlenJames L Gulley
Apr 21, 2012·Pharmacogenomics·Colin McCowan, Alastair M Thompson
Jul 2, 2015·Journal of Korean Medical Science·Hyoeun KimYun-Mi Song
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mei-Chuan HungJung-Der Wang
Jan 1, 2009·Zeitschrift für Psychosomatische Medizin und Psychotherapie·Jochen ErnstManfred E Beutel
May 13, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Su Jin LeeMyong Sei Sohn
Feb 26, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Mi-Kyung KimSang Yoon Park
May 17, 2013·Journal of Korean Medical Science·Dong Wook ShinJong Hyock Park
Mar 2, 2011·Oncology Nursing Forum·Ying Chun ZengAlice Yuen Loke
Aug 17, 2016·PloS One·Boyoung ParkMyong Cheol Lim
Jan 16, 2018·European Journal of Cancer Care·Y-H KimJ-S Kim
Oct 7, 2017·Medicine·Shu ChenXianquan Zhang
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Kyung-Hyun ChoiSeong Ho Han
Jan 16, 2019·JAMA Network Open·Mette Vestergaard JensenJeanette Falck Winther
Nov 30, 2019·Korean journal of family medicine·Jihun KangJungkwon Lee
May 28, 2019·The Journal of Clinical Hypertension·Sabine Karam
May 18, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Jung-Yun LeeKyung-Hyun Choi
Mar 22, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Else IbfeltSusanne Oksbjerg Dalton
Mar 23, 2021·Public Health·F TangE Vásquez
Dec 24, 2021·Science Progress·Ji-Su KimYeji Seo